All In Biotech

Drug Trial Radar · NCT06350123

Efficacy, Safety and Tolerability of Balcinrenone/Dapagliflozin Compared to Dapagliflozin in Adults With Chronic Kidney Disease

A Phase IIb, Multicenter, Randomised, Double-Blind, Dose-finding Study to Evaluate the Efficacy, Safety and Tolerability of Balcinrenone in Combination With Dapagliflozin Compared With Dapagliflozin in Patients With Chronic Kidney Disease and Albuminuria

Last checked: Nov 20, 2026Latest source record: Jun 26, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingRandomized with 324 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

324

Actual

Start

May 1, 2024

Primary completion

May 9, 2025

Study completion May 9, 2025

Sponsor

Lead sponsor
AstraZenecaAstraZeneca (AZN)
Sponsor type
Industry
First posted
Apr 5, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of the study is to evaluate the efficacy, safety and tolerability of balcinrenone/dapagliflozin compared with dapagliflozin alone on patients with chronic kidney disease (CKD) and albuminuria. This study will evaluate the effect of the balcinrenone/dapagliflozin on urinary albumin-to-creatinine ratio (UACR), compared with dapagliflozin in patients with CKD. This is a dose-finding study aiming to identify an optimal dose of balcinrenone/dapagliflozin for a future Phase III study in patients with CKD.

Conditions

  • Chronic Kidney Disease

Interventions

  • Balcinrenone/dapagliflozin 15 mg/10 mg and matching placebo for dapagliflozin 10 mgDrug

    1 capsule of balcinrenone/dapagliflozin 15 mg/10 mg and 1 tablet of matching placebo for dapagliflozin 10 mg once daily, oral use

  • Balcinrenone/dapagliflozin 40 mg/10 mg and matching placebo for dapagliflozin 10 mgDrug

    1 capsule of balcinrenone/dapagliflozin 40 mg/10 mg and 1 tablet of matching placebo for dapagliflozin 10 mg once daily, oral use

  • Dapagliflozin 10 mg and matching placebo for balcinrenone/dapa gliflozinDrug

    1 tablet of dapagliflozin 10 mg and 1 capsule of matching placebo for balcinrenone/dapagliflozin once daily, oral use

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Relative Change in Urine Albumin-to-Creatinine Ratio (UACR) From Baseline to Week 12Time frame: Baseline (Day 1) until Week 12 (Day 85)

Locations

92 sites in 15 countries. Site status is shown where the registry gives one.

  • Research Site

    Sheffield, Alabama

  • Research Site

    Glendale, California

  • Research Site

    Waterbury, Connecticut

  • Research Site

    Hialeah, Florida

  • Research Site

    Miami Lakes, Florida

  • Research Site

    Annapolis, Maryland

  • Research Site

    New Bern, North Carolina

  • Research Site

    El Paso, Texas

  • Research Site

    Houston, Texas

  • Research Site

    Houston, Texas

  • Research Site

    San Antonio, Texas

  • Research Site

    Ogden, Utah

  • Research Site

    Salt Lake City, Utah

  • Research Site

    Salt Lake City, Utah

  • Research Site

    Norfolk, Virginia

  • Research Site

    Linz, Austria

  • Research Site

    Sankt Pölten, Austria

  • Research Site

    Vienna, Austria

  • Research Site

    Vienna, Austria

  • Research Site

    Vienna, Austria

  • Research Site

    Vienna, Austria

  • Research Site

    Wels, Austria

  • Research Site

    Porto Alegre, Brazil

  • Research Site

    São Paulo, Brazil

  • Research Site

    São Paulo, Brazil

  • Research Site

    São Paulo, Brazil

  • Research Site

    São Paulo, Brazil

  • Research Site

    Burgas, Bulgaria

  • Research Site

    Dobrich, Bulgaria

  • Research Site

    Pleven, Bulgaria

  • Research Site

    Plovdiv, Bulgaria

  • Research Site

    Sofia, Bulgaria

  • Research Site

    London, Ontario, Canada

  • Research Site

    Waterloo, Ontario, Canada

  • Research Site

    Montreal, Quebec, Canada

  • Research Site

    Québec, Quebec, Canada

  • Research Site

    Changchun, China

  • Research Site

    Changzhou, China

  • Research Site

    Shanghai, China

  • Research Site

    Shanghai, China

Showing 40 of 92 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.